This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Meitheal Pharmaceuticals, Inc.
Meitheal Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates across various regions globally. Founded in 2015, the company has quickly established itself as a leader in the development and manufacturing of high-quality generic and specialty pharmaceuticals. Meitheal Pharmaceuticals focuses on a diverse range of therapeutic areas, including oncology, cardiovascular, and infectious diseases, offering a unique portfolio of products that meet stringent regulatory standards. The company is recognised for its commitment to innovation and quality, which has positioned it favourably in a competitive market. With a strong emphasis on research and development, Meitheal Pharmaceuticals continues to achieve significant milestones, contributing to improved patient outcomes and expanding access to essential medications.
DitchCarbon Score
How does Meitheal Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Meitheal Pharmaceuticals, Inc.'s score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Meitheal Pharmaceuticals, Inc.'s reported carbon emissions
Meitheal Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., from which it inherits emissions data and climate commitments. As of now, Meitheal Pharmaceuticals has not established any documented reduction targets or specific climate pledges. The absence of detailed emissions data suggests that the company may still be in the early stages of developing its sustainability strategy. The climate commitments and initiatives of Meitheal Pharmaceuticals are influenced by its parent company, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., which may have its own sustainability goals and emissions reduction strategies. However, specific details regarding these initiatives have not been disclosed. In summary, while Meitheal Pharmaceuticals, Inc. is part of a larger corporate family with potential climate commitments, it currently lacks specific emissions data and reduction targets. The company may benefit from aligning its strategies with those of its parent organisation to enhance its environmental impact and sustainability efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Meitheal Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
